权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

The Alzheimer's Disease Research Center at the University of California, Irvine

加州大学欧文分校阿尔茨海默病研究中心

基本信息

批准号：
10747262
负责人：
FRANK M LAFERLA
金额：
$ 0.61万
依托单位：
UNIVERSITY OF CALIFORNIA-IRVINE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-15 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10747262
关键词：
Address Adult Age Aged, 80 and over Alzheimer&apos s Disease Alzheimer&apos s disease pathology Alzheimer&apos s disease risk Autopsy Basic Science Biological Markers Brain Diseases California Clinical Clinical Sciences Cognitive Communities Consent County Data Data Set Development Diagnosis Dimensions Disease Disparity Down Syndrome Education Epidemic Ethnic Population Etiology Goals Image Impaired cognition Individual Knowledge Longevity Modernization Nature Oranges Outcome Pathogenesis Pathologic Patients Persons Populations at Risk Predisposition Productivity Recording of previous events Registries Research Research Personnel Resources Scientist Special Population Stains Training Translational Research Universities cell bank cohort in vivo induced pluripotent stem cell innovation insight interdisciplinary approach mild cognitive impairment neuropathology next generation novel prevent prodromal Alzheimer&apos s disease recruit resilience

项目摘要

UCI ADRC Overall Project Summary/Abstract The central theme of the University of California, Irvine Alzheimer's Disease Research Center (UCI ADRC) is to identify, quantify, and validate factors that influence the risk of Alzheimer's disease (AD) across the lifespan. Given its diverse and multifactorial nature, it is critical to understand the etiology and progression of this insidious brain disorder at multiple dimensions, including clinically and neuropathologically, and to employ novel scientific approaches so that we can advance knowledge and better diagnose, prevent and cure the disease. The UCI ADRC has a strong history of integrating basic, clinical, and translational science to gain insights into AD pathogenesis and to help meet some of the goals of the National Alzheimer's Project Act. First, our Center has a distinguished record of studying the disease in diverse patient cohorts: Uniform Data Set (UDS) Cohort, which includes cognitively normal individuals and individuals with mild cognitive impairment (prodromal AD); adults with Down syndrome, representing the largest genetically at-risk population for AD; and 90+, which show great disparity between AD pathology and cognitive loss and are among the oldest group of individuals to develop AD. Together, these cohorts enable interrogation of important novel questions related to age, susceptibility and resilience, using innovative outcomes ranging from in vivo biomarker characterization to modern pathological outcomes such as post-mortem imaging and microglial staining. Second, the UCI ADRC has a history of innovation that has helped advance the field; the development of the nation's first induced pluripotent stem cell bank for AD as part of the ADRC network and our recently established Consent-to- Contact recruitment registry are recent examples of this innovation. Third, our Center continues to evolve. Given the expertise, productivity, and resources devoted the study of special populations at UCI, we have initiated two Special Populations Cores, one focused on Down syndrome and one focused on the oldest old (90+). These Cores will interact with the other cores of the ADRC to produce novel data and resources available to ADRC investigators, including through our newly established Biomarker Core. Finally, we have established a new Research and Education Component in this proposal, which harnesses the long-standing passionate commitment to training the next generation of clinicians and scientists at UCI. In sum, the UCI ADRC brings energetic and innovative multi-dimensional and multidisciplinary approaches toward addressing the national epidemic of AD.

UCI ADRC总体